Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Enhancement of DNA micro-array analysis using a shear-driven micro-channel flow system.

Journal of chromatography. A

Pappaert K, Vanderhoeven J, Van Hummelen P, Dutta B, Clicq D, Baron GV, Desmet G.
PMID: 14558606
J Chromatogr A. 2003 Oct 03;1014(1):1-9. doi: 10.1016/s0021-9673(03)00715-5.

A very simple micro-channel flow system is used to investigate the potential gain in hybridization rate stemming from the induction of a convective flow past the surface of a DNA micro-array. Reporting on a series of preliminary experiments wherein...

Cite
Pappaert K, Vanderhoeven J, Van Hummelen P, et al. Enhancement of DNA micro-array analysis using a shear-driven micro-channel flow system. J Chromatogr A. 2003;1014(1):1-9doi: 10.1016/s0021-9673(03)00715-5.
Pappaert, K., Vanderhoeven, J., Van Hummelen, P., Dutta, B., Clicq, D., Baron, G. V., & Desmet, G. (2003). Enhancement of DNA micro-array analysis using a shear-driven micro-channel flow system. Journal of chromatography. A, 1014(1), 1-9. https://doi.org/10.1016/s0021-9673(03)00715-5
Pappaert, K, et al. "Enhancement of DNA micro-array analysis using a shear-driven micro-channel flow system." Journal of chromatography. A vol. 1014,1 (2003): 1-9. doi: https://doi.org/10.1016/s0021-9673(03)00715-5
Pappaert K, Vanderhoeven J, Van Hummelen P, Dutta B, Clicq D, Baron GV, Desmet G. Enhancement of DNA micro-array analysis using a shear-driven micro-channel flow system. J Chromatogr A. 2003 Oct 03;1014(1):1-9. doi: 10.1016/s0021-9673(03)00715-5. PMID: 14558606.
Copy Download .nbib Format: NLM
Genomic landscape of high-grade meningiomas.

NPJ genomic medicine

Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, Ducar M, Thorner AR, van Hummelen P, Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R.
PMID: 28713588
NPJ Genom Med. 2017;2. doi: 10.1038/s41525-017-0014-7. Epub 2017 Apr 26.

High-grade meningiomas frequently recur and are associated with high rates of morbidity and mortality. To determine the factors that promote the development and evolution of these tumors, we analyzed the genomes of 134 high-grade meningiomas and compared this information...

Cite
Bi WL, Greenwald NF, Abedalthagafi M, et al. Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017;2doi: 10.1038/s41525-017-0014-7.
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J., Gibson, W. J., Agarwalla, P. K., Horowitz, P., Schumacher, S. E., Esaulova, E., Mei, Y., Chevalier, A., Ducar, M., Thorner, A. R., van Hummelen, P., Stemmer-Rachamimov, A., Artyomov, M., Al-Mefty, O., Dunn, G. P., Santagata, S., Dunn, I. F., & Beroukhim, R. (2017). Genomic landscape of high-grade meningiomas. NPJ genomic medicine, 2. https://doi.org/10.1038/s41525-017-0014-7
Bi, Wenya Linda, et al. "Genomic landscape of high-grade meningiomas." NPJ genomic medicine vol. 2 (2017). doi: https://doi.org/10.1038/s41525-017-0014-7
Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, Ducar M, Thorner AR, van Hummelen P, Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R. Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017;2. doi: 10.1038/s41525-017-0014-7. Epub 2017 Apr 26. PMID: 28713588; PMCID: PMC5506858.
Copy Download .nbib Format: NLM
Painful pulsatile epigastric mass.

Journal of vascular surgery

Weiss R, Hirsch H, Standiford T, Van Bemmelen P.
PMID: 34688399
J Vasc Surg. 2021 Nov;74(5):1707. doi: 10.1016/j.jvs.2020.12.055.

No abstract available.

Cite
Weiss R, Hirsch H, Standiford T, et al. Painful pulsatile epigastric mass. J Vasc Surg. 2021;74(5):1707doi: 10.1016/j.jvs.2020.12.055.
Weiss, R., Hirsch, H., Standiford, T., & Van Bemmelen, P. (2021). Painful pulsatile epigastric mass. Journal of vascular surgery, 74(5), 1707. https://doi.org/10.1016/j.jvs.2020.12.055
Weiss, Robert, et al. "Painful pulsatile epigastric mass." Journal of vascular surgery vol. 74,5 (2021): 1707. doi: https://doi.org/10.1016/j.jvs.2020.12.055
Weiss R, Hirsch H, Standiford T, Van Bemmelen P. Painful pulsatile epigastric mass. J Vasc Surg. 2021 Nov;74(5):1707. doi: 10.1016/j.jvs.2020.12.055. PMID: 34688399.
Copy Download .nbib Format: NLM
Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers.

Journal of psychopharmacology (Oxford, England)

Wijnands S, Chang PC, Blauw GJ, van den Krogt J, Gieschke R, Schoerlin MP, van Brummelen P.
PMID: 22156310
J Psychopharmacol. 1989 Jan;3(1):36-44. doi: 10.1177/026988118900300107.

The interaction between tyramine and the new short-acting and reversible mono amine oxidase inhibitor moclobemide was investigated in a double-blind placebo-controlled study in six healthy volunteers. There were two consecutive study periods of 8 days during which the subjects...

Cite
Wijnands S, Chang PC, Blauw GJ, et al. Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol. 1989;3(1):36-44doi: 10.1177/026988118900300107.
Wijnands, S., Chang, P. C., Blauw, G. J., van den Krogt, J., Gieschke, R., Schoerlin, M. P., & van Brummelen, P. (1989). Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. Journal of psychopharmacology (Oxford, England), 3(1), 36-44. https://doi.org/10.1177/026988118900300107
Wijnands, S, et al. "Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers." Journal of psychopharmacology (Oxford, England) vol. 3,1 (1989): 36-44. doi: https://doi.org/10.1177/026988118900300107
Wijnands S, Chang PC, Blauw GJ, van den Krogt J, Gieschke R, Schoerlin MP, van Brummelen P. Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol. 1989 Jan;3(1):36-44. doi: 10.1177/026988118900300107. PMID: 22156310.
Copy Download .nbib Format: NLM
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF.

Oncotarget

Antonello ZA, Hsu N, Bhasin M, Roti G, Joshi M, Van Hummelen P, Ye E, Lo AS, Karumanchi SA, Bryke CR, Nucera C.
PMID: 29156680
Oncotarget. 2017 Sep 24;8(49):84743-84760. doi: 10.18632/oncotarget.21262. eCollection 2017 Oct 17.

PURPOSE: Papillary thyroid carcinoma (PTC) is the most frequent endocrine tumor. BRAFEXPERIMENTAL DESIGN: Following treatment with vemurafenib, we expanded a sub-population of cells with primary resistance and characterized them genetically and cytogenetically. We have used exome sequencing, metaphase chromosome...

Cite
Antonello ZA, Hsu N, Bhasin M, et al. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF. Oncotarget. 2017;8(49):84743-84760doi: 10.18632/oncotarget.21262.
Antonello, Z. A., Hsu, N., Bhasin, M., Roti, G., Joshi, M., Van Hummelen, P., Ye, E., Lo, A. S., Karumanchi, S. A., Bryke, C. R., & Nucera, C. (2017). Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF. Oncotarget, 8(49), 84743-84760. https://doi.org/10.18632/oncotarget.21262
Antonello, Zeus A, et al. "Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF." Oncotarget vol. 8,49 (2017): 84743-84760. doi: https://doi.org/10.18632/oncotarget.21262
Antonello ZA, Hsu N, Bhasin M, Roti G, Joshi M, Van Hummelen P, Ye E, Lo AS, Karumanchi SA, Bryke CR, Nucera C. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF. Oncotarget. 2017 Sep 24;8(49):84743-84760. doi: 10.18632/oncotarget.21262. eCollection 2017 Oct 17. PMID: 29156680; PMCID: PMC5689570.
Copy Download .nbib Format: NLM
Erratum: Genomic landscape of high-grade meningiomas.

NPJ genomic medicine

Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, A Ducar M, Thorner AR, van Hummelen P, O Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R.
PMID: 29263836
NPJ Genom Med. 2017 Sep 04;2:26. doi: 10.1038/s41525-017-0023-6. eCollection 2017.

[This corrects the article DOI: 10.1038/s41525-017-0014-7.].

Cite
Bi WL, Greenwald NF, Abedalthagafi M, et al. Erratum: Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017;2:26doi: 10.1038/s41525-017-0023-6.
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J., Gibson, W. J., Agarwalla, P. K., Horowitz, P., Schumacher, S. E., Esaulova, E., Mei, Y., Chevalier, A., A Ducar, M., Thorner, A. R., van Hummelen, P., O Stemmer-Rachamimov, A., Artyomov, M., Al-Mefty, O., Dunn, G. P., Santagata, S., Dunn, I. F., & Beroukhim, R. (2017). Erratum: Genomic landscape of high-grade meningiomas. NPJ genomic medicine, 226. https://doi.org/10.1038/s41525-017-0023-6
Bi, Wenya Linda, et al. "Erratum: Genomic landscape of high-grade meningiomas." NPJ genomic medicine vol. 2 (2017): 26. doi: https://doi.org/10.1038/s41525-017-0023-6
Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, A Ducar M, Thorner AR, van Hummelen P, O Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R. Erratum: Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017 Sep 04;2:26. doi: 10.1038/s41525-017-0023-6. eCollection 2017. PMID: 29263836; PMCID: PMC5677977.
Copy Download .nbib Format: NLM
Parenteral Pethidine for labour pain relief and substance use disorder: 20-year follow-up cohort study in offspring.

BMJ open

Pereira RR, Kanhai H, Rosendaal F, van Dommelen P, Swaab D, Rodrigues Pereira E, van de Wetering B.
PMID: 22649173
BMJ Open. 2012 May 30;2(3). doi: 10.1136/bmjopen-2011-000719. Print 2012.

OBJECTIVE: To determine whether use of intrapartum Pethidine pain analgesia increases the risk for substance use disorder in adult offspring.DESIGN: Analysis of data from a cohort study.SETTING: Academic hospital in Leiden, the Netherlands.PARTICIPANTS: 133 cases and 164 control individuals,...

Cite
Pereira RR, Kanhai H, Rosendaal F, et al. Parenteral Pethidine for labour pain relief and substance use disorder: 20-year follow-up cohort study in offspring. BMJ Open. 2012;2(3)doi: 10.1136/bmjopen-2011-000719.
Pereira, R. R., Kanhai, H., Rosendaal, F., van Dommelen, P., Swaab, D., Rodrigues Pereira, E., & van de Wetering, B. (2012). Parenteral Pethidine for labour pain relief and substance use disorder: 20-year follow-up cohort study in offspring. BMJ open, 2(3), . https://doi.org/10.1136/bmjopen-2011-000719
Pereira, Robert Rodrigues, et al. "Parenteral Pethidine for labour pain relief and substance use disorder: 20-year follow-up cohort study in offspring." BMJ open vol. 2,3 (2012). doi: https://doi.org/10.1136/bmjopen-2011-000719
Pereira RR, Kanhai H, Rosendaal F, van Dommelen P, Swaab D, Rodrigues Pereira E, van de Wetering B. Parenteral Pethidine for labour pain relief and substance use disorder: 20-year follow-up cohort study in offspring. BMJ Open. 2012 May 30;2(3). doi: 10.1136/bmjopen-2011-000719. Print 2012. PMID: 22649173; PMCID: PMC3367141.
Copy Download .nbib Format: NLM
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Nature medicine

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.
PMID: 29955181
Nat Med. 2018 Aug;24(8):1292. doi: 10.1038/s41591-018-0098-3.

In the version of this article originally published, some text above the "Tri-nucleotide sequence motifs" label in Fig. 2a appeared incorrectly. The text was garbled and should have appeared as nucleotide codes.Additionally, the labels on the bars in Fig....

Cite
Chapuy B, Stewart C, Dunford AJ, et al. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(8):1292doi: 10.1038/s41591-018-0098-3.
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., Staiger, A. M., Wala, J. A., Ducar, M. D., Leshchiner, I., Rheinbay, E., Taylor-Weiner, A., Coughlin, C. A., Hess, J. M., Pedamallu, C. S., Livitz, D., Rosebrock, D., Rosenberg, M., Tracy, A. A., Horn, H., van Hummelen, P., Feldman, A. L., Link, B. K., Novak, A. J., Cerhan, J. R., Habermann, T. M., Siebert, R., Rosenwald, A., Thorner, A. R., Meyerson, M. L., Golub, T. R., Beroukhim, R., Wulf, G. G., Ott, G., Rodig, S. J., Monti, S., Neuberg, D. S., Loeffler, M., Pfreundschuh, M., Trümper, L., Getz, G., & Shipp, M. A. (2018). Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature medicine, 24(8), 1292. https://doi.org/10.1038/s41591-018-0098-3
Chapuy, Bjoern, et al. "Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes." Nature medicine vol. 24,8 (2018): 1292. doi: https://doi.org/10.1038/s41591-018-0098-3
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug;24(8):1292. doi: 10.1038/s41591-018-0098-3. PMID: 29955181.
Copy Download .nbib Format: NLM
Preference-based measure of social participation from the Handicap Scale for Children.

Expert review of pharmacoeconomics & outcomes research

van Dommelen P, Schuller A, Detmar S, van den Berg B, Groothuis-Oudshoorn K.
PMID: 20528382
Expert Rev Pharmacoecon Outcomes Res. 2008 Jun;8(3):309-17. doi: 10.1586/14737167.8.3.309.

OBJECTIVE: To establish a model that estimates a preference-based measure (valuation) of social participation for children between 8 and 18 years of age from the Handicap Scale for Children (HSC), a validated questionnaire for children with a chronic illness.METHODS:...

Cite
van Dommelen P, Schuller A, Detmar S, et al. Preference-based measure of social participation from the Handicap Scale for Children. Expert Rev Pharmacoecon Outcomes Res. 2008;8(3):309-17doi: 10.1586/14737167.8.3.309.
van Dommelen, P., Schuller, A., Detmar, S., van den Berg, B., & Groothuis-Oudshoorn, K. (2008). Preference-based measure of social participation from the Handicap Scale for Children. Expert review of pharmacoeconomics & outcomes research, 8(3), 309-17. https://doi.org/10.1586/14737167.8.3.309
van Dommelen, Paula, et al. "Preference-based measure of social participation from the Handicap Scale for Children." Expert review of pharmacoeconomics & outcomes research vol. 8,3 (2008): 309-17. doi: https://doi.org/10.1586/14737167.8.3.309
van Dommelen P, Schuller A, Detmar S, van den Berg B, Groothuis-Oudshoorn K. Preference-based measure of social participation from the Handicap Scale for Children. Expert Rev Pharmacoecon Outcomes Res. 2008 Jun;8(3):309-17. doi: 10.1586/14737167.8.3.309. PMID: 20528382.
Copy Download .nbib Format: NLM
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

The Journal of molecular diagnostics : JMD

MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI.
PMID: 25157968
J Mol Diagn. 2014 Nov;16(6):660-72. doi: 10.1016/j.jmoldx.2014.06.004. Epub 2014 Aug 23.

Ongoing cancer genome characterization studies continue to elucidate the spectrum of genomic abnormalities that drive many cancers, and in the clinical arena assessment of the driver genetic alterations in patients is playing an increasingly important diagnostic and/or prognostic role...

Cite
MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014;16(6):660-72doi: 10.1016/j.jmoldx.2014.06.004.
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M., Adusumilli, R., Breneiser, M., Byrne, M., Chung, L., Conneely, J., Crosby, L., Garraway, L. A., Gong, X., Hahn, W. C., Hatton, C., Kantoff, P. W., Kluk, M., Kuo, F., Jia, Y., Joshi, R., Longtine, J., Manning, A., Palescandolo, E., Sharaf, N., Sholl, L., van Hummelen, P., Wade, J., Wollinson, B. M., Zepf, D., Rollins, B. J., & Lindeman, N. I. (2014). Prospective enterprise-level molecular genotyping of a cohort of cancer patients. The Journal of molecular diagnostics : JMD, 16(6), 660-72. https://doi.org/10.1016/j.jmoldx.2014.06.004
MacConaill, Laura E, et al. "Prospective enterprise-level molecular genotyping of a cohort of cancer patients." The Journal of molecular diagnostics : JMD vol. 16,6 (2014): 660-72. doi: https://doi.org/10.1016/j.jmoldx.2014.06.004
MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014 Nov;16(6):660-72. doi: 10.1016/j.jmoldx.2014.06.004. Epub 2014 Aug 23. PMID: 25157968; PMCID: PMC4210463.
Copy Download .nbib Format: NLM
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Nature medicine

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.
PMID: 29955182
Nat Med. 2018 Aug;24(8):1290-1291. doi: 10.1038/s41591-018-0097-4.

In the version of this article originally published, an asterisk was omitted from Fig. 1a. The asterisk has been added to the figure. Additionally, a "NOTCH2" label was erroneously included in Fig. 4a. The label has been removed. The...

Cite
Chapuy B, Stewart C, Dunford AJ, et al. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(8):1290-1291doi: 10.1038/s41591-018-0097-4.
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., Staiger, A. M., Wala, J. A., Ducar, M. D., Leshchiner, I., Rheinbay, E., Taylor-Weiner, A., Coughlin, C. A., Hess, J. M., Pedamallu, C. S., Livitz, D., Rosebrock, D., Rosenberg, M., Tracy, A. A., Horn, H., van Hummelen, P., Feldman, A. L., Link, B. K., Novak, A. J., Cerhan, J. R., Habermann, T. M., Siebert, R., Rosenwald, A., Thorner, A. R., Meyerson, M. L., Golub, T. R., Beroukhim, R., Wulf, G. G., Ott, G., Rodig, S. J., Monti, S., Neuberg, D. S., Loeffler, M., Pfreundschuh, M., Trümper, L., Getz, G., & Shipp, M. A. (2018). Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature medicine, 24(8), 1290-1291. https://doi.org/10.1038/s41591-018-0097-4
Chapuy, Bjoern, et al. "Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes." Nature medicine vol. 24,8 (2018): 1290-1291. doi: https://doi.org/10.1038/s41591-018-0097-4
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug;24(8):1290-1291. doi: 10.1038/s41591-018-0097-4. PMID: 29955182.
Copy Download .nbib Format: NLM
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Cancer cell

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.
PMID: 27479034
Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11.

No abstract available.

Cite
Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016;30(1):183doi: 10.1016/j.ccell.2016.06.008.
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S. C., Plana, O., Montero, J., Stevenson, K. E., Rao, P., Vadhi, R., Andreeff, M., Armand, P., Ballen, K. K., Barzaghi-Rinaudo, P., Cahill, S., Clark, R. A., Cooke, V. G., Davids, M. S., DeAngelo, D. J., Dorfman, D. M., Eaton, H., Ebert, B. L., Etchin, J., Firestone, B., Fisher, D. C., Freedman, A. S., Galinsky, I. A., Gao, H., Garcia, J. S., Garnache-Ottou, F., Graubert, T. A., Gutierrez, A., Halilovic, E., Harris, M. H., Herbert, Z. T., Horwitz, S. M., Inghirami, G., Intlekofer, A. M., Ito, M., Izraeli, S., Jacobsen, E. D., Jacobson, C. A., Jeay, S., Jeremias, I., Kelliher, M. A., Koch, R., Konopleva, M., Kopp, N., Kornblau, S. M., Kung, A. L., Kupper, T. S., LeBoeuf, N. R., LaCasce, A. S., Lees, E., Li, L. S., Look, A. T., Murakami, M., Muschen, M., Neuberg, D., Ng, S. Y., Odejide, O. O., Orkin, S. H., Paquette, R. R., Place, A. E., Roderick, J. E., Ryan, J. A., Sallan, S. E., Shoji, B., Silverman, L. B., Soiffer, R. J., Steensma, D. P., Stegmaier, K., Stone, R. M., Tamburini, J., Thorner, A. R., van Hummelen, P., Wadleigh, M., Wiesmann, M., Weng, A. P., Wuerthner, J. U., Williams, D. A., Wollison, B. M., Lane, A. A., Letai, A., Bertagnolli, M. M., Ritz, J., Brown, M., Long, H., Aster, J. C., Shipp, M. A., Griffin, J. D., & Weinstock, D. M. (2016). The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer cell, 30(1), 183. https://doi.org/10.1016/j.ccell.2016.06.008
Townsend, Elizabeth C, et al. "The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice." Cancer cell vol. 30,1 (2016): 183. doi: https://doi.org/10.1016/j.ccell.2016.06.008
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. PMID: 27479034.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries